An Examination of Moderna

Understanding the COVID-19 response for Moderna, a biotechnology company based out of the United States, and compiling the current outlooks regarding vaccinations, development of a diversified product line, and garnering a competitive edge in the biotechnology space is a costly endeavor Moderna is attempting to transverse. Declining revenues, rising costs, and low sales of Moderna's current product have deteriorated the value base. The recent increase in share price is motivated by anticipation of a potential avian flu outbreak and response. This study attempts to shed light on the current financial condition of Moderna.